secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001672688-26-000086
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M
-----------------------------------------------------------------------------

- Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.
- Initiated MAD dosing in AGA participants; preliminary PK supports 2-3 injections over six months.
- Expanded pipeline with ABS-202, a novel anti-PRLR antibody for undisclosed I&I indication.
- Q1 revenue $0.2M, net loss $29.6M; cash $125.7M sufficient into first half of 2028.
- Anticipates reporting preliminary safety, tolerability, PK data in Q2 2026; proof-of-concept in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/0001672688-26-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/absc-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001672688-26-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer